

PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/616,359
	Filing Date	July 9, 2003
	First Named Inventor	Bizzarro
	Art Unit	1626
	Examiner Name	Wright, Sonya N
Total Number of Pages in This Submission	Attorney Docket Number	20400 US6

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Eileen M. Ebel
Signature	
Date	March 4, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date March 4, 2004			
Typed or printed	Eileen M. Ebel		
Signature		Date	March 4, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Fred Thomas Bizzarro, et. al.

Group: 1626

Serial No. 10/616,359, filed July 9, 2003

Examiner: Wright, Sonya N

Docket No.: 20400 US6

For: HETEROAROMATIC GLUCOKINASE ACTIVATORS

RESPONSE UNDER 35 U S C § 121

Nutley, New Jersey 07110
March 4, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated February 6, 2004, Applicants provide the following remarks.

In response to the requirement for restriction, Applicants elect Group II, claims 1-149 and 267-278, directed to compounds of formula I wherein R⁴ is thiazole and thiadiazole.

In terms of a species election, Applicants request that the Examiner begin the search for compounds in which R² is methylsulfonyl, i.e., SO₂CH₃. Applicants identify species Example numbers 3, 12, 13, 89 and 97. In these Examples, R³

is cyclopentyl. In Examples 3 and 13, R¹ is hydrogen. In Examples 12 and 97, R¹ is Cl. In Example 89, R¹ is CF₃.

Applicants traverse the requirement for restriction, however.

The U.S. Patent Office is required to examine on the merits the entirety of generic claims. Applicants point out that it is well-established law that restriction within a single claim cannot be sustained under 35 U.S.C. §121. As is stated in *In re Weber*, 198 USPQ 328 (CCPA 1978), at pages 331-332:

“§121 provides the Commissioner with the authority to promulgate rules designed to *restrict an application* to one of several claimed inventions when those inventions are found to be “independent and distinct.” It does not, however, provide a basis for an examiner acting under the authority of the Commissioner to *reject* a particular *claim* on that same basis.” (Emphasis in original text.)

If the Patent Office were to withdraw applicants' claims in part from further consideration due to an intra-claim restriction, the requirement amounts in fact to a rejection, see *In re Hass*, 179 USPQ 623, 625 (CCPA 1973).

Applicants have the right under U.S. patent law to claim their invention using the limitations that they regard as essential to delineate the invention, as long as the requirements of 35 U.S.C. §112 are met.

The law does not authorize the U.S. Patent Office to derive its own concept of a generic form of the claimed subject matter and require that it be carved out of existing claims. Applicants have the right under U.S. patent law to claim their invention using the limitations they provide to delineate the invention, as long as the requirements of 35 USC § 112 are met. See *In re Weber* at 331 and *In re Wolfrum and Gold*, 179 USPQ 620, 622 (CCPA 1973).

Serial No. 10/616,359


Filed: July 9, 2003

Also, the Examiner is required to follow the U.S. Patent Office procedures set forth in MPEP § 809. The Examiner must perform a search for all claims readable on the elected species. The elected species should be examined. If the species is patentable, then the next species should be examined, and so forth, until an unpatentable species is found. If no species is found unpatentable, then the generic claim should be allowed.

Applicants request that the intra-claim restriction requirement be withdrawn.

It is believed that no fees are due. If a fee is owing, please charge our deposit account no. 08-2525

Respectfully submitted,



Attorney for Applicant(s)
Eileen M. Ebel
(Reg. No. 37,316)
340 Kingsland Street
Nutley, NJ 07110
Telephone (973) 235-4391
Telefax: (973) 235-2363

139849